XML 37 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business and Product Line Acquisitions - Additional Information (Detail) (USD $)
 1 Months Ended 1 Months Ended
Oct. 01, 2012
Macleod Pharmaceuticals
Jul. 01, 2013
SyrVet, Inc.
Jul. 01, 2013
SyrVet, Inc.
Trademarks
Jan. 01, 2013
Scidera Genomics,LLC
Business Acquisition [Line Items]        
Cash consideration for purchase of business $ 9,918,000 $ 10,012,000   $ 3,400,000
Contingent consideration potential payment 100,000 1,500,000    
Purchase price allocation for accounts receivable 353,000 747,000    
Purchase price allocation for inventory 1,238,000 2,195,000    
Purchase price allocation for fixed assets 300,000 556,000   246,000
Purchase price allocation for current liabilities 82,000 226,000    
Purchase price allocation for deferred tax liabilities, current 2,054,000      
Allocation of purchase price for contingent consideration potential payment 100,000 700,000    
Purchase price allocation for intangible assets 5,542,000 3,010,000   1,570,000
Purchase price allocation for current assets       35,000
Sales from International Markets   30.00%    
Purchase price allocation for non-amortizable trademarks     $ 347,000  
Finite lived intangible assets, useful life   15 years